Calamos Advisors
ITCI

Calamos Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Calamos Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,668
Closed -$2.31M – 998
2024
Q4 		$2.31M Sell
27,668
-3,952
-12% -$325K 0.01% 597
2024
Q3 		$2.31M Buy
31,620
+15,216
+93% +$1.14M 0.01% 598
2024
Q2 		$1.12M Buy
16,404
+7,590
+86% +$526K 0.01% 636
2024
Q1 		$610K Buy
8,814
+662
+8% +$45.5K ﹤0.01% 692
2023
Q4 		$584K Buy
+8,152
New +$469K ﹤0.01% 718
2022
Q3 		– Sell
-93,772
Closed -$5.35M – 1353
2022
Q2 		$5.35M Sell
93,772
-4,940
-5% -$280K 0.02% 670
2022
Q1 		$6.04M Buy
+98,712
New +$5.13M 0.02% 646

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return